IDEAYA Biosciences (IDEAYA Biosciences) Debt-to-EBITDA : -0.01 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is IDEAYA Biosciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

IDEAYA Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.15 Mil. IDEAYA Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.26 Mil. IDEAYA Biosciences's annualized EBITDA for the quarter that ended in Mar. 2024 was $-199.74 Mil. IDEAYA Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for IDEAYA Biosciences's Debt-to-EBITDA or its related term are showing as below:

IDYA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.2 Med: -0.11 Max: -0.02
Current: -0.02

During the past 7 years, the highest Debt-to-EBITDA Ratio of IDEAYA Biosciences was -0.02. The lowest was -0.20. And the median was -0.11.

IDYA's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.37 vs IDYA: -0.02

IDEAYA Biosciences Debt-to-EBITDA Historical Data

The historical data trend for IDEAYA Biosciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDEAYA Biosciences Debt-to-EBITDA Chart

IDEAYA Biosciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.16

-0.20

-0.11

-0.06

-0.02

IDEAYA Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.03	-0.02	-0.02	-0.02	-0.01

Competitive Comparison of IDEAYA Biosciences's Debt-to-EBITDA

For the Biotechnology subindustry, IDEAYA Biosciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IDEAYA Biosciences's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where IDEAYA Biosciences's Debt-to-EBITDA falls into.

IDEAYA Biosciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

IDEAYA Biosciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.747	+	1.125)	/	-130.421
	=	-0.02

IDEAYA Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.151	+	1.256)	/	-199.74
	=	-0.01

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

IDEAYA Biosciences (NAS:IDYA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

IDEAYA Biosciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of IDEAYA Biosciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

IDEAYA Biosciences (IDEAYA Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IDEAYA Biosciences Inc (NAS:IDYA) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

30J:Germany 30J:Germany

Address

7000 Shoreline Court, Suite 350, South San Francisco, CA, USA, 94080

Website

https://www.ideayabio.com

IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.

Executives

Yujiro S Hata	director, officer: President and CEO	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Briseno Andres Ruiz	officer: See Remarks	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Jason Throne	officer: VP, General Counsel	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Paul A. Stone	officer: SVP, General Counsel	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Darrin Beaupre	officer: SVP, Chief Medical Officer	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Catherine J Mackey	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Michael Anthony White	officer: SVP, Chief Scientific Officer	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Michael P. Dillon	officer: SVP, Chief Scientific Officer	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Susan L. Kelley	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Mark Lackner	officer: SVP, Head of Biology	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Andrew J. Schwab	10 percent owner, Former 10% holder	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
John D Diekman	10 percent owner, Former 10% holder	C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Scott M Rocklage	10 percent owner, Former 10% holder	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Co-investors Iv, L.p.	10 percent owner, Former 10% holder	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107